Case Study

Amgen Adopts Technology Solution For Antibody Discovery And Cell Line Development

Biotechnology Scientist pipetting sample into a multi well plate iStock-1294915154

As one of the early customers to have adopted the Berkeley Lights platform, Amgen has been able to continuously push the capabalities of the Beacon® optofluidic system. Since adoption, Amgen has expanded their usage of the platform from antibody discovery to cell line development. By putting it into practice in their antibody discovery work they were able to take about four months off the normal timeline. They have also implemented the system as their standard method for cell line development, and are looking to extend their success in these areas to other applications. Continue reading to learn more about this transformative tool.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online